Analysts Issue Forecasts for ANRO Q1 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for Alto Neuroscience in a research note issued on Friday, March 21st. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.53) per share for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience's Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience Stock Performance

Shares of ANRO traded down $0.09 during trading hours on Monday, reaching $2.42. 222,480 shares of the company's stock traded hands, compared to its average volume of 358,793. Alto Neuroscience has a twelve month low of $2.37 and a twelve month high of $18.31. The firm has a market capitalization of $65.13 million and a price-to-earnings ratio of -0.95. The business's fifty day simple moving average is $3.53 and its two-hundred day simple moving average is $5.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.09.

Remove Ads

Institutional Investors Weigh In On Alto Neuroscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new position in shares of Alto Neuroscience in the 4th quarter worth approximately $3,542,000. Point72 Asset Management L.P. raised its holdings in Alto Neuroscience by 73.1% during the 4th quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company's stock worth $7,158,000 after buying an additional 714,461 shares during the period. Franklin Resources Inc. lifted its stake in Alto Neuroscience by 95.3% during the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company's stock valued at $13,965,000 after buying an additional 595,673 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of Alto Neuroscience by 397.6% in the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company's stock worth $2,631,000 after buying an additional 496,976 shares during the period. Finally, Northern Trust Corp increased its position in shares of Alto Neuroscience by 198.1% in the fourth quarter. Northern Trust Corp now owns 587,135 shares of the company's stock worth $2,484,000 after acquiring an additional 390,190 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.